Related references
Note: Only part of the references are listed.Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma
Justin C. Moser et al.
ACTA ONCOLOGICA (2020)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
[Anonymous]
NATURE REVIEWS DRUG DISCOVERY (2018)
Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials
Tzu-Rong Peng et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Petros Fessas et al.
SEMINARS IN ONCOLOGY (2017)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Immune surveillance of tumors
Jeremy B. Swann et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Cancer despite immunosurveillance: immunoselection and immunosubversion
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Share Paper
